|
| Status |
Public on Jun 12, 2018 |
| Title |
Discovery of Selective Estrogen Receptor Covalent Antagonists (SERCAs) for the treatment of ERa(WT) and ERa(MUT) breast cancer. |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
Expression profiling by high throughput sequencing
Genome binding/occupancy profiling by high throughput sequencing
|
| Summary |
This SuperSeries is composed of the SubSeries listed below.
|
| |
|
| Overall design |
Refer to individual Series
|
| |
|
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jun 11, 2018 |
| Last update date |
Mar 26, 2019 |
| Contact name |
Zhenhua Wu |
| E-mail(s) |
zhenhuawu75@gmail.com
|
| Phone |
6179592279
|
| Organization name |
H3 Biomedicine
|
| Street address |
300 Technology Square floor 5
|
| City |
Cambridge |
| State/province |
MA |
| ZIP/Postal code |
02139 |
| Country |
USA |
| |
|
| Platforms (3) |
| GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
| GPL18573 |
Illumina NextSeq 500 (Homo sapiens) |
| GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
| Samples (85)
|
|
| This SuperSeries is composed of the following SubSeries:
|
| GSE115564 |
ESR1 mutations maintain higher ER pathway activity relative to vehicle and ERa-WT controls following treatment with Raloxifene or fulvestrant. |
| GSE115607 |
ChIP-Seq analysis of estrogen deprived MCF7 cells treated with H3B-5942 and standards of care compounds |
| GSE115608 |
Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds |
| GSE115609 |
Transcriptional profiling of MCF7 cells treated with H3B05942, E2, or standard of care compounds |
|
| Relations |
| BioProject |
PRJNA475560 |
Less...
More...